French gene therapy products developer Transgene has managed to raise €63m ($54m) from a rights offering on the Nouveau Marché despite the fact that its share price had plummeted to well below the offer price.

The issue was originally planned to raise €80m, but mustered €63m after the share price fell below the offer price the day after the terms for the rights issue were set.